KCT0003045招募中未知
Effect of Intravenous Zoledronic Acid on Bone Mineral Density in Osteoporosis Patients
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 50(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •? Adults over 50 years old.
- •? diagnosed as osteoporosis (T-score = 2.5).
排除标准
- •? Creatinin clearance rate < 35mL/min
- •? Hypersensitivity in Bisphosphonates
- •? Hypersensitivity of Zoledronic acid
- •? Serum calcium concentration = 8.4mg/dL
- •? Pretnant or breast feeding
研究者
相似试验
进行中（未招募）
不适用
„Effect of intravenous Zoledronic Acid on Bone Metabolism given over 4 month in patients with prostate cancer or breast cancer and bone metastasis. A prospective, single-arm multicenter study” (ZoTect) - ZoTectEUCTR2005-002132-94-DEovartis Pharma GmbH405
进行中（未招募）
1 期
Zoledronic acid in patients with metastatic prostate cancer treated with abiraterone acetate: impact on bone mineral densityMetastatic castration-resistant prostate cancerMedDRA version: 18.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001146-34-FRCentre Oscar Lambret
招募中
4 期
To compare the effect of preoperative use of Zoledronic acid versus placebo on postoperative bone health in patients with primary hyperparathyroidismCTRI/2019/10/021762PGIMER Chandigarh
进行中（未招募）
不适用
Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine or endocrine treatment - ProBONE IIEUCTR2004-002832-24-DEovartis Pharma GmbH
进行中（未招募）
不适用
Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment - ProBONE IEUCTR2004-002831-14-DEovartis Pharma GmbH